I like the plan, that the CEO is targeting CE mark this year. If it doesn't happen, not going to look good so must have some confidence. This seems to be a result of the review done last year so I think some credit must go to Neil.
Cash burn is not that high ($460k per month) and I read that they are fully funded to end of 2016.
I think sales will only happen 1st half of 2016 (possibly Q4 2015 if they get CE mark in Q3 but I think they will need to build sales team/distribution networks which will take some time) but still, that is not long to go.
Seems quite aggressive which is good, at least they are not sitting on their hands waiting for things to happen.
Once they start selling in EU, New Zealand, Canada and Australia, they can fund the FDA trial off revenues.
If it performs anything like Sirtex, wow! I am keen to buy in but I think mal is pushing the price up, eh mal
OSL Price at posting:
9.6¢ Sentiment: Buy Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)